nach oben

Erschienen in:

01.05.2011

Matrix Metalloproteinases 2 and 9 Fail to Influence Drug-Induced Neuroapoptosis in Developing Rat Brain

verfasst von: Ortrud Uckermann, Hella Luksch, Vanya Stefovska, Yvonne Hoehna, Jenny Marzahn, Marlen Theil, Mila Pesic, Tomasz Górkiewicz, Maciej Gawlak, Grzegorz M. Wilczynski, Leszek Kaczmarek, Chrysanthy Ikonomidou

Erschienen in: Neurotoxicity Research | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Matrix metalloproteinases (MMPs) play an essential role in tissue repair, cell death, and morphogenesis. The aim of the present study was to investigate potential involvement of selected MMPs in the pathogenesis of neuronal apoptosis induced by the NMDA antagonist MK-801 (dizocilpine) or the GABA_A agonist phenobarbital in infant rats, transgenic rats overexpressing MMP-9 and MMP-9 knockout mice. Seven-day-old rats or knockout mice received intraperitoneal injections of MK-801, 1 mg/kg, or phenobarbital, 50 mg/kg. At different survival intervals following administration of the compounds (1–72 h), pups were sacrificed, tissue from different brain regions was isolated, and the expression and activity of MMP-2 and MMP-9 were analyzed by real-time PCR, western blot, and zymography. In addition, brains were fixed and processed for TUNEL staining. In all the brain regions analyzed, we found an increased number of TUNEL-positive cells 24 h after administration of MK-801. After treatment, we detected no significant increase in MMP-2 or MMP-9 mRNA expression in cortical areas. No changes in the MMP-9 protein expression or gelatinolytic activity of MMP-2 were observed in conjunction with MK-801 or phenobarbital-induced neuroapoptosis in any brain region analyzed. The extent of neurodegeneration induced by MK-801 or phenobarbital was not altered in MMP-9 transgenic rats and was increased in MMP-9 knockout mice compared to wild-type rats and mice. Treatment with the panmetalloproteinase inhibitor GM6001 did not confer protection against MK-801-induced apoptotic cell death in the developing rat brain. Our results suggest that activation of MMP-9 and MMP-2 does not contribute to pathogenesis of neuronal apoptosis caused by NMDA antagonists or GABA_A agonists in the developing rat and mouse brain.

Amantea D, Corasaniti MT, Mercuri NB, Bernardi G, Bagetta G (2008) Brain regional and cellular localization of gelatinase activity in rats that have undergone transient middle cerebral artery occlusion. Neuroscience 152(1):8–17PubMedCrossRef

Ashai M, Wang X, Mori T, Sumii T, Jung J-C, Moskowitz AA, Fini E, Lo EH (2001) Effects of matrix metalloproteinase 9 gene knockout on proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724–7732

Bittigau P, Sifringer M, Genz K, Reith E, Pospischil D, Govindarajalu S, Dzietko M, Pesditschek S, Mai I, Dikranian K, Olney JW, Ikonomidou C (2002) Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci 99(23):15089–15094PubMedCrossRef

Chen W, Hartman R, Ayer R, Marcantonio S, Kamper J, Tang J, Zhang JH (2009) Matrix metalloproteases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. J Neurochem 111:726–736PubMedCrossRef

Dikranian K, Ishimaru MJ, Tenkova T, Labruyere J, Qin YQ, Ikonomidou C, Olney JW (2001) Apoptosis in the in vivo mammalian forebrain. Neurobiol Dis 8:359–379PubMedCrossRef

Gasche Y, Fujimura Y, Copin J, Kawase M, Masengale J, Chan PH (1999) Early appearance of activated MMP-9 after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 19:1020–1028PubMedCrossRef

Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA (2002) S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297:1186–1190PubMedCrossRef

Hansen HH, Briem T, Dzietko M, Sifringer M, Voss A, Rzeski W, Zdzisinska B, Thor F, Heumann R, Stepulak A, Bittigau P, Ikonomidou C (2004) Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol Dis 16(2):440–453PubMedCrossRef

Heo JH, Lucero J, Abumiya T, Koizol JA, Copeland BR, Del Zoppo GJ (1999) Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 19:624–633PubMedCrossRef

Ikonomidou C, Bosch F, Miksa J, Bittigau P, Vöckler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW (1999) Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283(5398):70–74PubMedCrossRef

Ishimaru MJ, Ikonomidou C, Tenkova TI, Der TC, Dikranian K, Sesma MA, Olney JW (1999) Distinguishing excitotoxic from apoptotic neurodegeneration in the developing rat brain. J Comp Neurol 408:461–476PubMedCrossRef

Jevtovic-Todorovic V, Hartman RE, Izumi Y, Benshoff ND, Dikranian K, Zorumski CF, Olney JW, Wozniak DF (2003) Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci 23:876–882PubMed

Kaindl AM, Koppelstaetter A, Nebrich G, Stuwe J, Sifringer M, Zabel C, Klose J, Ikonomidou C (2008) Brief alteration of NMDA or GABAA receptor-mediated neurotransmission has long term effects on the developing cerebral cortex. Mol Cell Proteomics 7(12):2293–2310PubMedCrossRef

Lee SR, Lo EH (2004) Induction of caspase-mediated cell death by matrix metalloproteinases in cerebral endothelial cells after hypoxia-reoxygenation. J Cereb Blood Flow Metab 24:720–727PubMedCrossRef

Lema Tomé CM, Miller R, Bauer C, Smith C, Blackstone K, Leigh A, Busch J, Turner CP (2008) Decline in age-dependent, MK801-induced injury coincides with developmental switch in parvalbumin expression: somatosensory and motor cortex. Dev Psychobiol 50(7):665–679PubMedCrossRef

Lo EH, Dalkara T, Moskowitz MA (2003) Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4:399–415PubMedCrossRef

Lukashev ME, Werb Z (1998) ECM signaling: orchestrating cell behavior and misbehavior. Trends Cell Biol 8:437–441PubMedCrossRef

Lyall A, Swanson J, Liu C, Blumenthal TD, Turner CP (2009) Neonatal exposure to MK801 promotes prepulse-induced delay in startle response time in adult rats. Exp Brain Res 197(3):215–222PubMedCrossRef

Maddahi A, Chen Q, Edvinsson L (2009) Enhanced cerebrovascular expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 via the MEK/ERK pathway during cerebral ischemia in the rat. BMC Neurosci 10:56PubMedCrossRef

Manabe S, Gu Z, Lipton SA (2005) Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Investig Opthalmol Vis Sci 46(12):4747–4753CrossRef

Michaluk P, Mikasova L, Groc L, Frischknecht R, Choquet D, Kaczmarek L (2009) Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin beta1 signaling. J Neurosci 29(18):6007–6012PubMedCrossRef

Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J (2001) Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32:1759–1766PubMedCrossRef

Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alverez-Sabin J (2003) Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107:598–603PubMedCrossRef

Morita-Fijimura Y, Fujimura M, Gasche Y, Copin J, Chan PH (1999) Overexpression of copper and zinc superoxide dismutase in transgenic mice prevents the induction and activation of matrix metalloproteinases after cold injury induced brain trauma. J Cereb Blood Flow Metab 20:130–138CrossRef

Nagase H, Woessner JF (1999) Matrix metalloproteinases: a minireview. J Biol Chem 274:21491–21494PubMedCrossRef

Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Balcerzyk M, Okulski P, Okulski P, Dzwonek J, Costa RM, Costa RM, Silva AJ, Kaczmarek L, Huntley GW (2006) Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci 15 26(7):1923–1934CrossRef

Noble LJ, Donovan F, Igarashi T, Goussev S, Werb Z (2002) Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 22:5726–5735

Olney JW, Young C, Wozniak DF, Jevtovic-Todorovic V, Ikonomidou C (2004) Do pediatric drugs cause developing neurons to commit suicide? Trends Pharmacol Sci 25:135–139PubMedCrossRef

Papadia S, Soriano FX, Leveille F, Martel MA, Dakin KA, Hansen HH, Kaindl A, Sifringer M, Fowler J, Stefovska V et al (2008) Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 11:476–487PubMedCrossRef

Ranasinghe HS, Williams CE, Christophidis LJ, Mitchell MD, Fraser M, Scheepens A (2009) Proteolytic activity during cortical development is distinct from that involved in hypoxic ischemic injury. Neuroscience 158(2):732–744 Epub 2008 Aug 14PubMedCrossRef

Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC (1998) Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. Stroke 29:1020–1030PubMed

Rosenberg GA, Navratril M, Barone F, Feuerstein G (1996) Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 16:360–366PubMedCrossRef

Shigemori Y, Katayama Y, Mori T, Maeda T, Kawatama T (2006) Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. Acta Neurochir 96:130–133CrossRef

Sifringer M, Stefovska V, Zentner I, Hansen B, Stepulak A, Knaute C, Marzahn J, Ikonomidou C (2007) The role of matrix metalloproteinases in infant traumatic brain injury. Neurobiol Dis 25(3):526–535PubMedCrossRef

Stefovska V, Czuczwar M, Smitka M, Czuczwar P, Kis J, Kaindl AM, Turski L, Turski WA, Ikonomidou C (2008) Sedative and anticonvulsant drugs suppress postnatal neurogenesis. Ann Neurol 64(4):434–445PubMedCrossRef

Svedin P, Hagberg H, Sävman K, Zhu C, Mallard C (2007) Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. J Neurosci 27(7):1511–1518PubMedCrossRef

Turner CP, Debenedetto D, Liu C (2009) NMDAR blockade-induced neonatal brain injury: reversal by the calcium channel agonist BayK 8644. Neurosci Lett 450(3):292–295PubMedCrossRef

Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z (1998) MMP-9 is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93:411–422PubMedCrossRef

Wang X, Jung J, Ashai M, Chwang W, Russo L, Moskowitz MA, Dixon CE, Fini ME, Lo EH (2000) Effects of matrix metalloproteinase-9 knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 20:7037–7042PubMed

Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW, Lo EH (2003) Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9:1313–1317PubMedCrossRef

West MJ, Gundersen HJ (1990) Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 296:1–22PubMedCrossRef

Wilczynski GM, Konopoacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P, Wawrzyniak M, Malinowska M, Okulski P, Kolodziej LR, Konopka W, Duniec K, Mioduszewska B, Nikolaev E, Walczak A, Owczarek D, Gorecki DC, Zuschratter W, Ottersen OP, Kaczmarek L (2008) Important role of matrix metalloproteinase-9 in epileptogenesis 10. J Cell Biol 180(5):1021–1035PubMedCrossRef

Yang Y, Candelario-Jalil E, Thompson JF, Cuadrado E, Estrada EY, Rosell A, Montaner J, Rosenberg GA (2010) Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J Neurochem 112(1):134–149PubMedCrossRef

Yong VW (2005) Metalloproteinases: mediators of pathology and regeneration in CNS. Nat Neurosci 6:931–944CrossRef

Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR (1998) Matrix metalloproteinases and disease of the CNS. Trends Neurosci 21:75–80PubMedCrossRef

Zhang JW, Deb S, Gottschall PE (1998) Regional and differential expression of gelatinases in rat brain after systemic kainic acid or bicuculline administration. Eur J Neurosci 10(11):3358–3368PubMedCrossRef

Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, Wang X, Lo EH (2006) Role of matrix metalloproteinase in delayed cortical responses after stroke. Nat Med 12(4):441–445PubMedCrossRef

Titel: Matrix Metalloproteinases 2 and 9 Fail to Influence Drug-Induced Neuroapoptosis in Developing Rat Brain
verfasst von: Ortrud Uckermann
Hella Luksch
Vanya Stefovska
Yvonne Hoehna
Jenny Marzahn
Marlen Theil
Mila Pesic
Tomasz Górkiewicz
Maciej Gawlak
Grzegorz M. Wilczynski
Leszek Kaczmarek
Chrysanthy Ikonomidou
Publikationsdatum: 01.05.2011
Verlag: Springer-Verlag
Erschienen in: Neurotoxicity Research / Ausgabe 4/2011
Print ISSN: 1029-8428
Elektronische ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-010-9211-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Ethanol Increases TIEG2–MAO B Cell Death Cascade in the Prefrontal Cortex of Ethanol-Preferring Rats

Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins

Efficacy of Novel Acridine Derivatives in the Inhibition of hPrP90-231 Prion Protein Fragment Toxicity

Development and Validation of a Screening Assay for the Evaluation of Putative Neuroprotective Agents in the Treatment of Parkinson’s Disease

Exposure to Pyrithiamine Increases β-Amyloid Accumulation, Tau Hyperphosphorylation, and Glycogen Synthase Kinase-3 Activity in the Brain